N. Heney

W. Shipley, A. Althausen, G. Prout, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy.

W. Shipley, C. Fung, R. Young, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.

A. Zietman, W. Shipley, R. Young, 2001, Urology.

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03.

B. Donnelly, W. Shipley, C. Perez, 1998, The Journal of urology.

Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival.

W. Shipley, G. Prout, N. Heney, 1985, The Journal of urology.

Bladder-sparing approaches to invasive disease

A. Zietman, J. Efstathiou, W. Shipley, 2006, World Journal of Urology.

Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer.

A. Zietman, W. Shipley, A. Althausen, 1997, International journal of radiation oncology, biology, physics.

Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.

J. Efstathiou, W. Shipley, W. Mcdougal, 2012, The Journal of urology.

The influence of perinephric fat involvement on survival in patients with renal cell carcinoma extending into the inferior vena cava.

N. Heney, B. Nocks, 1982, The Journal of urology.

Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 1997, Seminars in surgical oncology.

Bladder preservation by combined modality therapy for invasive bladder cancer.

A. Zietman, W. Shipley, L. Kachnic, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective bladder preservation by combination treatment of invasive bladder cancer.

W. Shipley, A. Althausen, N. Heney, 1993, The New England journal of medicine.

Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin.

L. Marks, W. Shipley, G. Prout, 1988, International journal of radiation oncology, biology, physics.

Bladder preservation: optimizing radiotherapy and integrated treatment strategies

R. Mak, A. Zietman, W. Shipley, 2008, BJU international.

Transitional cell carcinoma of renal pelvis.

G. Prout, N. Heney, J. Daly, 1982, Urology.

Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation.

A. Zietman, W. Shipley, A. Althausen, 1997, International journal of radiation oncology, biology, physics.

A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 1998, The Journal of urology.

A PHASE MI TRIAL OF TRANSURETHRAL SURGERY COMBINED WITH RADIATION FOLLOWED BY SELECTIVE BLADDER PRESERVATION IN OPERABLE PATIENTS WITH MUSCLE INVADING BLADDER CANCER CONCURRENT CISPLATIN, 5-FLUOROURACIL AND TWICE DAILY

A. Zietman, W. Shipley, A. Althausen, 1998 .

Opportunities with combined modality therapy for selective organ preservation in muscle‐invasive bladder cancer

A. Zietman, W. Shipley, A. Althausen, 1996, Journal of surgical oncology.

Interval report of a phase I-II study utilizing multiple modalities in the treatment of invasive bladder cancer. A bladder-sparing trial.

W. Shipley, G. Prout, N. Heney, 1991, The Urologic clinics of North America.

Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.

W. Shipley, A. Althausen, G. Prout, 1990, The Journal of urology.

L. True, B. Donnelly, W. Shipley, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trimodality therapy in the management of muscle-invasive bladder cancer: a selective organ-preserving approach

A. Zietman, W. Shipley, A. Althausen, 2008 .

An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.

A. Zietman, W. Shipley, A. Althausen, 1999, The Journal of urology.

Ta and T1 bladder cancer: location, recurrence and progression.

G. Prout, N. Heney, J. Daly, 1982, British journal of urology.

Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer

A. Zietman, J. Efstathiou, W. Shipley, 2013, Current Urology Reports.

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease.

A. Zietman, W. Shipley, N. Heney, 1996, Urology.

Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy.

R. Colvin, S. Schwartz, W. Shipley, 1992, The Journal of urology.

Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.

A. Niemierko, M. Michaelson, A. Zietman, 2017, European urology.

NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.

D. Grignon, A. Zietman, H. Sandler, 2016 .

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder

M. Michaelson, A. Zietman, W. Shipley, 2004, British Journal of Cancer.

An Update of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer

A. Zietman, W. Shipley, A. Althausen, 1998, European Urology.

Can chemo-radiotherapy plus transurethral tumor resection make cystectomy unnecessary for invasive bladder cancer?

W. Shipley, N. Heney, D. Kaufman, 1990, Oncology.

RTOG 9706: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapy

John D. Roberts, Christopher U. Jones, W. Shipley, 2001 .

Selective bladder preservation by combined modality treatment of invasive bladder cancer: 10-Year outcome

A. Zietman, W. Shipley, N. Heney, 2001 .

First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.

N. Heney, 1986, Urology.

Superficial bladder cancer: progression and recurrence.

S. Loening, W. Frable, M. Hafermann, 1983, The Journal of urology.

Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.

A. Gown, E. Oliva, M. Amin, 2013, Human pathology.

Condyloma acuminatum of the bladder and ureter: case report and review of the literature.

R. Young, M. Keating, N. Heney, 1985, The Journal of urology.

Primary adenocarcinoma of urinary bladder.

N. Heney, J. Daly, B. Nocks, 1983, Urology.

Positive urinary cytology in patients without evident tumor.

G. Prout, N. Heney, J. Daly, 1977, The Journal of urology.

Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.

D. Trump, N. Heney, N M Heney, 1988, The Journal of urology.

Long-Term Outcomes of Organ Preservation in Patients with Small Cell Carcinoma of the Bladder

Chin-Lee Wu, W. Mcdougal, N. Heney, 2015, Urologia Internationalis.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

D. Grignon, A. Zietman, H. Sandler, 2017, The New England journal of medicine.

Renal Hilar Lymph: Effects of Diuresis on Flow and Composition in Dogs

N. Heney, C. C. O'morchoe, P. J. O'Morchoe, 1970, Circulation research.

Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 1996, Seminars in oncology.

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.

A. Zietman, H. Sandler, R. Uzzo, 2014, International journal of radiation oncology, biology, physics.

Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy O

D. Grignon, H. Sandler, Chin-Lee Wu, 2005, International journal of radiation oncology, biology, physics.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-2003. A 33-year-old woman with gross hematuria.

R. Young, N. Heney, 2003, The New England journal of medicine.

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

R. Mak, A. Zietman, J. Efstathiou, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural history of superficial bladder cancer. Prognostic features and long-term disease course.

N. Heney, N M Heney, 1992, The Urologic clinics of North America.

Ileal conduit hemorrhage secondary to portal hypertension.

T. Hensle, N. Heney, A. Waltman, 1978, Urology.

The integration of chemotherapy, radiotherapy and transurethral surgery in bladder-sparing approaches for patients with invasive tumors.

W. Shipley, A. Althausen, G. Prout, 1990, Progress in clinical and biological research.

The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.

L. True, W. Sause, W. Shipley, 2000, The oncologist.

Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

H. Sandler, K. Bae, J. Efstathiou, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radio-chemotherapy for invasive carcinoma of the bladder.

W. Shipley, A. Althausen, G. Prout, 1992, Frontiers of radiation therapy and oncology.

Erectile impotence as complication of direct vision cold knife urethrotomy.

D. McDermott, A. Althausen, N. Heney, 1981, Urology.

Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01.

Christopher U. Jones, R. Mak, H. Sandler, 2016, Urologic oncology.

Autosuturing device in intestinal urinary conduits.

T. Hensle, N. Heney, S. Dretler, 1978, Urology.

Outcomes of Selective Bladder Preservation in the Elderly Treated With Conservative Surgery and Chemoradiation

A. Niemierko, A. Zietman, P. Gray, 2013 .

The results of concurrent chemo‐radiotherapy for recurrence after treatment with bacillus Calmette‐Guérin for non‐muscle‐invasive bladder cancer: is immediate cystectomy always necessary?

A. Zietman, W. Shipley, N. Heney, 2009, BJU international.

Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

A. Zietman, H. Sandler, W. Shipley, 2009, Urology.

Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer

A. Niemierko, A. Zietman, J. Efstathiou, 2018, The Journal of urology.

The renal lymphatic system during obstructed urine flow.

N. Heney, C. C. O'morchoe, P. O'Morchoe, 1971, The Journal of urology.

Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.

Andrzej Niemierko, Anthony L Zietman, A. Niemierko, 2013, International journal of radiation oncology, biology, physics.

Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient.

A. Zietman, W. Shipley, L. Kachnic, 1996, The cancer journal from Scientific American.

The effect of intravesical thio-tepa on normal and tumor urothelium.

P. Nieh, G. Prout, N. Heney, 1978, The Journal of urology.

42 A phase trial of transurethral surgery plus cisplatin and radiation therapy followed by either selective bladder preservation or radical cystectomy for patients with muscle-invading bladder cancer but without hydronephrosis

A. Zietman, W. Shipley, A. Althausen, 1997 .

Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233.

R. Mak, A. Zietman, J. Efstathiou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgery: Selective bladder-preserving therapy for muscle-invasive cancer

W. Shipley, N. Heney, D. Kaufman, 2009, Nature Reviews Clinical Oncology.

Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973-1981).

W. Shipley, A. Althausen, G. Prout, 1988, NCI monographs : a publication of the National Cancer Institute.

Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233.

R. Mak, A. Zietman, J. Efstathiou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Organ conservation as an alternative to radical cystectomy for invasive bladder cancer: urodynamic and quality of life evaluation of patients treated by trimodality therapy

A. Zietman, W. Shipley, A. Althausen, 2002 .

The Long-Term Success of Local Radiation Therapy in Preventing Tumor Regrowth in the Treated Field

W. Shipley, A. Althausen, G. Prout, 1988 .

Long-term Outcomes After Bladder-Preserving Combined Modality Therapy for Patients With Muscle-Invasive Bladder Cancer

A. Niemierko, M. Michaelson, A. Zietman, 2015 .

Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA

D. Grignon, A. Zietman, H. Sandler, 2016 .

308: An Update of Selective Bladder Preservation Using Combined Modality Treatment in Invasive Bladder Cancer: Long Term Outcome Reveals a Low Risk of Invasive Recurrence and a High Probability of Bladder Preservation

A. Zietman, W. Shipley, A. Althausen, 2004 .

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone.

L. Verhey, A. Zietman, M. Goitein, 1995, International journal of radiation oncology, biology, physics.